| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 6682- | DCA, | QC, | Dichloroacetate and Quercetin Prevent Cell Proliferation, Induce Cell Death and Slow Tumor Growth in a Mouse Model of HPV-Positive Head and Neck Cancer |
| - | in-vivo, | HNSCC, | MEER |
| 6681- | DCA, | Dichloroacetate (DCA) in Cancer Care |
| 6679- | DCA, | GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial |
| - | Trial, | Melanoma, | NA |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1876- | DCA, | Chemo, | In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines |
| - | in-vivo, | Lung, | H727 |
| 1875- | DCA, | Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells |
| - | in-vitro, | neuroblastoma, | NA | - | in-vivo, | NA, | NA |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1881- | DCA, | Chemo, | Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report |
| - | in-vitro, | NA, | HT1080 | - | in-vitro, | NA, | WI38 | - | Case Report, | Var, | NA |
| 1884- | DCA, | Sal, | Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1870- | DCA, | Rad, | Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation |
| - | in-vitro, | Pca, | PC3 |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | NA, | NA |
| 1867- | DCA, | Chemo, | Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | NA |
| 1866- | DCA, | MET, | BTZ, | Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner |
| - | in-vivo, | NA, | NA |
| 1887- | DCA, | GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate |
| - | in-vitro, | Var, | NA |
| 1885- | DCA, | Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 6674- | Deg, | Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway |
| - | in-vitro, | Lung, | H1975 |
| 6671- | Deg, | A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy |
| - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 6699- | DFC, | Mitochondrial H2O2 Is a Central Mediator of Diclofenac-Induced Hepatocellular Injury |
| - | vitro+vivo, | Nor, | NA |
| 6706- | DFC, | MET, | Frontiers | Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells |
| - | in-vitro, | AML, | U937 |
| 6708- | DFC, | Repurposing Drugs as Expanding Cancer Treatment Palette: Diclofenac |
| 6709- | DFC, | Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 6696- | DFC, | MET, | Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma |
| - | in-vitro, | GBM, | GBM |
| 6694- | DFC, | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| - | Review, | Var, | NA |
| 6665- | DFE, | Cytotoxic Effect of Phoenix dactylifera (Iraqi Date) Leaves and Fruits Extracts against Breast Cancers Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 | - | in-vitro, | BC, | MCF7 |
| 4455- | DFE, | Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | 3T3 |
| 6760- | DHA, | Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans |
| - | Trial, | Nor, | NA |
| 6745- | DHA, | Omega-3 fatty acid DHA induces ferroptosis in colorectal cancer patient-derived organoids and drug-tolerant cells |
| - | in-vitro, | CRC, | HT29 |
| 6747- | DHA, | erastin, | ELOVL5 Regulates Ferroptosis in Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| - | Trial, | BC, | NA |
| 6754- | DHA, | Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial |
| - | Trial, | AD, | NA |
| 6756- | DHA, | Omega-3 Fatty Acids and Cognitive Function |
| - | Review, | AD, | NA |
| 6757- | DHA, | EPA, | Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation |
| - | Review, | Var, | NA |
| 6721- | DHCA, | Dihydrocaffeic Acid—Is It the Less Known but Equally Valuable Phenolic Acid? |
| - | Review, | Nor, | NA |
| 2169- | dietF, | Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy |
| - | Case Report, | Ovarian, | NA |
| 2152- | dietFMD, | Prolonged Nightly Fasting and Breast Cancer Prognosis |
| - | Analysis, | BC, | NA |
| 1844- | dietFMD, | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 1845- | dietFMD, | Fasting and fasting mimicking diets in cancer prevention and therapy |
| - | Review, | Var, | NA |
| 1863- | dietFMD, | Chemo, | Effect of fasting on cancer: A narrative review of scientific evidence |
| - | Review, | Var, | NA |
| 1847- | dietFMD, | VitC, | Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers |
| - | in-vitro, | PC, | PANC1 |
| 1848- | dietFMD, | Chemo, | Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial |
| - | Trial, | BC, | NA |
| 1849- | dietFMD, | The emerging role of fasting-mimicking diets in cancer treatment |
| - | Review, | Var, | NA |
| 1850- | dietFMD, | Fasting-mimicking diet remodels gut microbiota and suppresses colorectal cancer progression |
| - | in-vivo, | CRC, | NA |
| 1846- | dietFMD, | VitC, | A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer |
| - | Study, | Var, | NA |
| 1853- | dietFMD, | Impact of Fasting on Patients With Cancer: An Integrative Review |
| - | Review, | Var, | NA |
| 1854- | dietFMD, | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
| - | Review, | Var, | NA |
| 1860- | dietFMD, | Chemo, | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
| 1843- | dietFMD, | BTZ, | Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia |
| - | in-vivo, | CLL, | NA |
| 1842- | dietFMD, | Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment |
| - | Trial, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid